Conclusions
MYELOFIBROSIS
These findings suggest that momelotinib provides clinically relevant symptom benefits in the JAK inhibitor‐naïve and JAK inhibitor‐exposed settings.Longitudinalmixed‐effect model repeated measure analyses support and expand upon landmarksymptom results in the completed phase III SIMPLIFY studies of momelotinib inMF. Momelotinibprovides consistent and clinically relevant symptom benefits for JAKinhibitor‐naïve and JAK inhibitor‐exposed patients with myelofibrosis.
